Weinberg V - Search Results

1

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Fong L, et al. Among authors: weinberg v. Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529. Cancer Res. 2009. PMID: 19147575 Clinical Trial.

2

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

3

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Rosenberg JE, et al. Cancer. 2007 Aug 1;110(3):556-63. doi: 10.1002/cncr.22811. Cancer. 2007. PMID: 17577218 Free article. Clinical Trial.

4

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. Harzstark AL, et al. Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8. Cancer. 2011. PMID: 21387258 Free article. Clinical Trial.

5

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.

Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Harzstark AL, et al. Cancer. 2011 Jun 1;117(11):2419-25. doi: 10.1002/cncr.25810. Epub 2010 Dec 29. Cancer. 2011. PMID: 24048789 Free article. Clinical Trial.

6

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.

Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Aggarwal RR, et al. Clin Genitourin Cancer. 2015 Jun;13(3):e191-8. doi: 10.1016/j.clgc.2014.12.004. Epub 2014 Dec 9. Clin Genitourin Cancer. 2015. PMID: 25557266 Clinical Trial.

7

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Kim W, et al. Among authors: weinberg v. Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21. Clin Cancer Res. 2014. PMID: 25336698 Free PMC article. Clinical Trial.

8

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Kwek SS, et al. Among authors: weinberg v. Cancer Immunol Res. 2015 Sep;3(9):1008-16. doi: 10.1158/2326-6066.CIR-14-0227. Epub 2015 May 12. Cancer Immunol Res. 2015. PMID: 25968455 Free PMC article. Clinical Trial.

9

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.

Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Rini BI, et al. Among authors: weinberg v. J Urol. 2006 Jun;175(6):2087-91. doi: 10.1016/S0022-5347(06)00261-8. J Urol. 2006. PMID: 16697809

10

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Rini BI, et al. Among authors: weinberg v. Cancer. 2006 Jul 1;107(1):67-74. doi: 10.1002/cncr.21956. Cancer. 2006. PMID: 16736512 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

189 results

Search Page

Filters